Google
LBRX — LB PHARMACEUTICALS INC COMMON STOCK (Healthcare >> Biotechnology)
LBRX FAQ
What is LBRX's ROE?
LB PHARMACEUTICALS INC COMMON STOCK reports a Return on Equity (ROE) of -10.34%.
What is LBRX's dividend yield?
LB PHARMACEUTICALS INC COMMON STOCK offers a dividend yield of 0.00%.
What is LBRX's Deepscope Quality Score?
Deepscope rates LBRX's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy LBRX?
Deepscope's AI Timing Score for LBRX is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does LBRX belong to?
LB PHARMACEUTICALS INC COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 29.40
Price
0.87
(3.05%)
Day Change
|
|
|---|
LBRX, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
47% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 80 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 29.40 |
| PBV / Sector |
2.16 / 4.75
|
| Earning Per Share | -1.41 |
| PE / Sector |
N/A / 17.65
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
4.47 M
GREAT
|
| Average 1W Daily Value |
4.23 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-09 09:40:02 |
| Symbol | LBRX |
| Name | LB PHARMACEUTICALS INC COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 28.68 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 818.14 / 9,000.42 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: One Pennsylvania Plaza, New York, NY, United States, 10119
Phone: 212 605 0300
Website: https://lbpharma.us
Sector: Healthcare >> Biotechnology
Description: LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
